|
Rethinking
R&D
As more Indian pharma companies hive off their R&D units,
Viveka Roychowdhury analyses the methods behind the moves
2008 may well be a watershed year for the Indian pharmaceutical
industry. Five to six major Indian pharma companies, with
a few more sitting on the fence, have announced plans to hive
off their New Chemical Entity (NCE) research units into stand-alone
companies.
Zydus
Cadila, Prolong ink drug discovery deal
Ahmedabad-based Zydus Cadila and Prolong Pharmaceuticals Inc,
a US-based, venture-backed drug delivery research and development
company, have announced a collaboration for development of
a next generation therapeutic protein, 'PEG-EPO', for the
treatment of severe anemia.
Orchid
gets formulation facilty approval; collaborates with Cellworks
Orchid Chemicals and Pharmaceuticals has announced that its
formulation facilities comprising the Cephalosporin plant
and Penicillin plant have been approved by the Medicines Control
Council (MCC), South Africa.
Elder
Pharmaceuticals to market anti-osteoarthritic nutritional
supplement
Elder Pharmaceuticals has recently signed an in-licensing
agreement with GNOSIS S p A, Italy.
Maneesh
Pharmaceuticals acquires Kopran's brand Smyle
Smyle, the flagship over the counter brand of Kopran, has
been bought over by Mumbai based Maneesh Pharmaceuticals for
Rs 52.88 crore.
Department
of Scientific and Industrial Research accredits LifeCell
The Department of Scientific and Industrial Research (DSIR)
have recognised the R&D division of LifeCell.
Wockhardt
enters into a strategic alliance to market Cetirizine tablets
in the US
Pharmaceutical and biotechnology major Wockhardt received
approval for an ANDA from the United States Food and Drug
Administration (US FDA) for marketing the tablets containing
five mg and 10 mg Cetirizine Hydrochloride, which is used
for treating various forms of allergy.
Alembic
acquires API manufacturing unit
Alembic has announced the acquisition of an Active Pharmaceutical
Ingredients (API) manufacturing facility of Nirayu for Rs
17.50 crore. It is a US FDA approvable facility.
Dr
Reddy's launches Supanac
Dr Reddy's Laboratories has launched Supanac (Diclofenac potassium
immediate release 50 mg tablets) in India, increasing its
offering in the Rs 2,700 crore NSAID (Non-steroidal Anti-inflammatory
drugs) market according to June MAT '07 IMS ORG.
IBPL
to market biotech products in Gulf
Intas Biopharmaceuticals (IBPL) has firmed up plans to supply
and market indigenously developed biotech products in the
Gulf.
Divesting
APIs
As Big Pharma sells its API units, contract manufacturing
players use this opportunity to acquire scale. Suja Nair
reviews recent deals
Troikaa
unveils 'painless painkiller' injection
Ahmedabad-based Troikaa Pharmaceuticals unveiled a new version
of its painkiller injection, Dynapar AQ one ml, which causes
no pain while being injected.
Wellspring
to provides radiology services to Hiranandani hospital
Nicholas Piramal (NPILs) subsidiary, Wellspring, is partnering
with Dr L H Hiranandani Hospital, which has recently been
accorded NABA accreditation.
Events
ISCR
meet discusses clinical research challenges in India
ISCR's first annual conference had a very timely theme: leaping
into the global arena. Manjusha Morgaonkar reports
IDMA
annual celebrations highlight exciting times ahead
Indian pharma industry got together to celebrate IDMA's 46th
Annual Day. Manjusha Morgaonkar reports
'Our
strategy is to cement the web of relationships'
Recognised as an export house by the Indian Government, Flamingo
Pharmaceuticals has extensive experience in global markets.
Ashwin Thacker, Managing Director, Flamingo Pharma outlines
some strategies to enter regulated markets, in conversation
with Arshiya Khan
|
